New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Slides:

Advertisements

Similar presentations

Farxiga™ - Dapagliflozin

Advertisements

Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 5.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

What's New in Basal Insulin for Diabetes

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Global Projections for Diabetes:

What Comes Second?.

Insulin Innovation.

Insulin/GLP-1 Agonist Combinations

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Updates on Outcomes for Novel T2D Therapies

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Updates Abound.

SGLT2 Inhibitors in the Modern Era: Why and Where?

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Impacting CV Risk With Diabetes Medications

Tailoring Hemophilia Prophylaxis Therapy

Impacting CV Risk With Diabetes Medications

GLP-1 Receptor Agonists: How Early Is Appropriate?

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Case Study Role of DPP-4 Inhibitors

Tackling CV Risk in T2DM.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Early and Intensive T2D Management:

Insulin/GLP-1 Agonist Combinations

Insulin Innovation.

Novel Approaches in T1D Management

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Novel Approaches to T1D Management

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

The Role of the Kidney in Glucose Control

Dual SGLT1/SGLT2 Inhibition in T1D

Insulin in Diabetes Management: Effective Patient Selection Is Key

Statins, Obesity, and Hyperlipidemia

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Add-On Therapy to Insulin in T1DM Management

Patient Selection for Modern T2D Agents

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

2015 EASD In Review: CV Risk management in t2dm

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Fixed-Ratio Combination Therapy in T2DM

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Top Tips in Evidence-Based Care for HFrEF

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

Fresh perspectives ON BASAL Insulins in diabetes care

The Challenge of Insulin Titration

Presentation transcript:

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors

Program Overview

Glycemic Control in T1DM

Risks Associated With T1DM

Limitations of Insulin Therapy for T1DM

Noninsulin Therapy for T1DM: Pramlintide

T2DM Therapies for T1DM: Metformin

T2DM Therapies for T1DM: GLP-1 RAs

T2DM Therapies for T1DM: SGLT Inhibitors

SGLT1/2 Inhibitors

Potential Benefit of SGLT1/2 Inhibitors for Patients With T1DM

Clinical Trials With SGLT Inhibitors for T1DM

Sotagliflozin for T1DM: inTandem Program

inTandem 3: Results

inTandem 3: Other Efficacy Endpoints

inTandem 3: Hypoglycemia and DKA

inTandem 3: Insulin Dose

Dapagliflozin in Patients With Inadequately Controlled T1DM: DEPICT Trials

Managing DKA: Key Points for Clinicians

Clinical Protocol for Managing the DKA Risk With SGLT Inhibitors

Clinical Protocol for Managing the DKA Risk With SGLT Inhibitors (cont)

Additional Considerations for Clinicians

Conclusion

Abbreviations

Abbreviations (cont)